| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Liquidia Corporation$77.93
-4.12 (-5.06%)
C 45Pipeline Score Overvalued Pharma · Commercial
Market Cap
5.42 B
EPS
0.24
P/E Ratio
430.65 $
Value Trade
76.51 M
SEC Financials
Q1 2026Dilution Risk
Revenue
132.87 M
R&D Expenses
12.57 M
Operating CF
52.99 M
Total Assets
401.53 M
Total Liabilities
292.95 M
Equity
108.58 M
D/E Ratio
12,345
5.61 %
Week
69.29 %
1 Month
76.4 %
3 Month
117.32 %
6 Month
2,093.53 %
5 Year
389.8 %
All Time
Cash Data
Cash Position
222.79 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
1.17 M
52 Week Range
11.85 - 62.30
% held by Insiders
16.62 %
% held by Institutions
67.33 %
Enterprise Value
5.38 B
Total Shares
88.89 M
Short %
20.48 %
Float Shares
64.36 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Liquidia Corporation
229Total events
0Upcoming
99Tier-1 (high impact)
2020 – 2026Coverage
Event history 229
Jun 30, 2026
◆Timing GuidanceYUTREPIAApprovedPresentation
Potential additional $25M funding if YUTREPIA net sales exceed $100M by June 30, 2026
Jun 30, 2026
◆Milestone PaymentYUTREPIAApprovedCorporate
Potential $25M tranche upon mutual agreement after aggregate net sales of YUTREPIA exceed $100M by June 30, 2026
Mar 31, 2026
▲Enrollment UpdateYUTREPIAApprovedTrial
More than 4,500 unique patient prescriptions
PAH and PH-ILDsource ↗
Mar 5, 2026
●Quarterly UpdateCorporate
Q4 and full year 2025 financial results and business update webcast
Feb 2026
◆Quarterly UpdateCorporate
Full-year 2025 audited financial results expected in February 2026
Jan 14, 2026
◆Oral PresentationPresentation
Liquidia presentation at 44th Annual J.P. Morgan Healthcare Conference
2026
◆Trial InitiationL606Trial
Global pivotal placebo-controlled efficacy study for L606 in PH-ILD
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
2026
◆Trial InitiationYUTREPIAApprovedTrial
Pivotal study of YUTREPIA for PH-COPD
pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD)source ↗
Q4 2025
▲Quarterly UpdateYUTREPIAApprovedCorporate
Preliminary Q4 2025 YUTREPIA net sales of $90.1 million
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
Drug Pipeline Intelligence
C45
Pipeline Score $1.2B
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.2x
rNPV / MCap Top 66%
Small Cap (rank 311 of 911)
Percentile RankLiquidia Corporation carries a moderate pipeline score (45/100), with $1.9B risk-adjusted pipeline value, led by L606 in Pulmonary Arterial Hypertension (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L606 Small molecule | Pulmonary Hypertension Due to Lung Disease (Disorder) | Phase 3 | NCT07285655 | 43% | $742M | RECRUITING | 344 | VERY_FAST | B (65) | Dec 1, 2031 | LOW_RISK | LOW Jun 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LQDA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LQDA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LQDALiquidia Corporation Announces Inclusion in the S&P SmallCap 600 Index MORRISVILLE, N.C. (
Liquidia Corporation announced its inclusion in the S&P SmallCap 600 Index, effective June 22, 2026. This milestone is seen as a testament to the company’s growth and operational excellence in developing innovative therapies for respiratory and vascular diseases. The CEO, Dr. Roger Jeffs, highlighted the significance of this achievement and the ongoing commitment to improving patient care. The inclusion in the index is expected to enhance the company's visibility in the investment sector.
Read more →LQDALiquidia Corporation Reports First Quarter 2026 Financial Results YUTREPIA (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient pres
Liquidia Corporation announced its Q1 2026 financial results, highlighting net product sales of approximately $130 million for YUTREPIA, its inhalation powder for treating pulmonary arterial hypertension and related conditions. The company reported a net income of $52.9 million and achieved positive adjusted EBITDA for the third consecutive quarter. Additionally, Liquidia initiated further clinical studies to expand its treatment offerings in serious pulmonary and vascular diseases, showcasing a strategic focus on enhancing patient care.
Read more →LQDALiquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Achieved YUTREPIA net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth
Liquidia Corporation has reported strong financial results for the fourth quarter and full year 2025, notably achieving $148.3 million in net product sales from YUTREPIA. The company experienced its second consecutive quarter of profitability, which reflects increasing adoption of YUTREPIA in clinical practice. Plans for 2026 include expanding prescriber adoption, growing the sales force, and advancing L606 into pivotal trials. However, the company also faced significant increases in general and administrative expenses, which could indicate challenges ahead.
Read more →LQDA▲ +12.9%on this news· ran to +26% by day 3
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year
Liquidia Corporation has announced preliminary estimates showing YUTREPIA net product sales of about $90.1 million for Q4 2025 and $148.3 million for the full year. The company credits its successful launch across multiple patient populations, indicating confidence from physicians and effective execution by its team. Looking forward, Liquidia plans to further develop its clinical pipeline, including advancements for YUTREPIA and its extended-release formulation, L606, addressing significant unmet needs in respiratory diseases.
Read more →LQDALiquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update Recorded $51.7 million in net product sales of YUTREPIA as launch momentum continues Achieved profitability in the first ful
Liquidia Corporation reported its financial results for the third quarter of 2025, showcasing significant advancements and profitability achieved through the launch of YUTREPIA. The company recorded net product sales of $51.7 million, with over 2,000 prescriptions written. Liquidia's CEO highlighted the ongoing positive reception of YUTREPIA among prescribers and patients. Additionally, the company is focused on expanding the therapeutic profile of YUTREPIA and moving forward with its L606 program.
Read more →LQDA▲ +13.7%on this news
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update YUTREPIA surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and
Liquidia Corporation reported its second quarter 2025 financial results, marking a significant milestone with the FDA approval of YUTREPIA. The inhalation powder has been rapidly adopted, with over 900 prescriptions written within 11 weeks post-approval. Financially, however, the company experienced a net loss that increased from the previous year, largely due to rising operational costs, including legal fees tied to ongoing litigation. Despite the financial losses, strong early demand and positive clinical evidence for YUTREPIA's efficiency indicate promising growth potential in the market for pulmonary arterial hypertension treatments.
Read more →LQDALiquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of
Liquidia Corporation announced it has received $50 million from Healthcare Royalty following its first commercial sale of YUTREPIA, an inhalation powder for pulmonary arterial hypertension. This funding comes after a court ruling denied a request for an injunction from United Therapeutics. The financing is set to support further commercial launch efforts and manufacturing expansion. Liquidia aims to achieve profitability without additional capital, bolstered by early sales momentum of YUTREPIA.
Read more →LQDALiquidia Schedules First Commercial Shipment of YUTREPIA (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPI
Liquidia Corporation announced its first commercial shipment of YUTREPIA (treprostinil) inhalation powder, following FDA approval on May 23, 2025, for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The shipment, occurring just five days post-approval, signals the company's intention to quickly address patient needs. However, Liquidia faces ongoing litigation from United Therapeutics over patent infringement, intensifying uncertainty around the commercialization of YUTREPIA.
Read more →LQDAU.S. FDA Approves Liquidia's YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) FDA's approval
Liquidia Corporation announced the FDA's approval of YUTREPIA, a novel inhalation powder for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This innovative treatment offers improved deep-lung delivery through a low-effort inhalation device. Despite the positive news, Liquidia faces legal challenges from United Therapeutics regarding patent infringement, which could impede the commercial launch of YUTREPIA. The company's commercial team is preparing to launch the product and engage with healthcare providers and patients about its benefits.
Read more →LQDALiquidia Corporation Provides Update on Litigation Filed by United Therapeutics New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR's 782 pa
Liquidia Corporation announced that United Therapeutics filed a complaint against it in the U.S. District Court for the Middle District of North Carolina, claiming infringement of U.S. Patent No. 11,357,782 regarding YUTREPIA, an inhalation therapy for pulmonary hypertension. While UTHR seeks to prevent Liquidia from commercializing YUTREPIA, the FDA's approval process remains unaffected with a goal date set for May 24, 2025. Liquidia's CEO expressed confidence in defending against the lawsuit, citing previous success in invalidating related patents.
Read more →LQDALiquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update Awaiting FDA action on YUTREPIA NDA with a PDUFA goal date of
Liquidia Corporation reported its financial results for the first quarter of 2025, revealing a net loss of $38.4 million. As the FDA's PDUFA goal date for YUTREPIA approaches on May 24, 2025, Liquidia is working to prepare for a potential launch. The company also announced the full enrollment of Cohort A in its ASCENT study, which is evaluating YUTREPIA's tolerability and efficacy. A recent court ruling dismissed a challenge to YUTREPIA's NDA amendment, enhancing Liquidia's operational stability. Additionally, Liquidia secured financing to support ongoing and future clinical development efforts.
Read more →LQDAItem 8. Financial Statements and Supplementary Data LIQUIDIA CORPORATION FINANCIAL STATEMENTS TABLE OF CONTENTS Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) F-2 Consolidated Balance Sheets as o
Liquidia Corporation's financial statements raise concerns about the company's future viability. The report highlights recurring losses and indicates substantial doubt regarding the company's ability to continue as a going concern. Additionally, the company has revised its accounting treatment for amendments in a major financing agreement, signaling potential instability in financial management. The audit opinion confirmed that the financial statements present a fair view of the company's financial position in compliance with U.S. accounting principles.
Read more →LQDADistrict Court Dismisses Dispute Filed by United Therapeutics Against Liquidia Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIA FDA can grant final approv
Liquidia Corporation announced that the U.S. District Court dismissed a cross-claim filed by United Therapeutics regarding its NDA for YUTREPIA. The Court found that United Therapeutics did not establish standing for their challenge against the PH-ILD indication added to the treatment label. Liquidia's CEO expressed satisfaction with the ruling and looked forward to potential final FDA approval for YUTREPIA, which is set for May 24, 2025.
Read more →LQDALiquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA (treprostinil) Inhalation Powder FDA sets PDUFA goal date of
Liquidia Corporation has announced the FDA's acceptance of its New Drug Application resubmission for YUTREPIA (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA acknowledged the resubmission as a complete response to the previous action letter from August 2024. A Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025, has been set, marking the next crucial step towards final approval.
Read more →LQDALiquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update Targeting final FDA approval of YUTREPIA after expiration of regulatory exclusivity on
Liquidia Corporation (NASDAQ: LQDA) released its financial results for the year ending December 31, 2024, reporting a net loss of $130.4 million. The company is targeting final FDA approval for its inhalation powder YUTREPIA for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with exclusivity set to expire on May 23, 2025. Liquidia has secured an additional financing of up to $100 million to strengthen its position and continue advancements in clinical trials. However, the decrease in revenue and ongoing litigation pose challenges.
Read more →LQDALiquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million MORRISVILLE, N.C.
Liquidia Corporation has amended its agreement with HealthCare Royalty to obtain up to $100 million in financing. This funding will support the development of YUTREPIA, a treatment for pulmonary arterial hypertension and related conditions. With optimism surrounding the forthcoming FDA approval, the company's leadership believes the funds will help achieve profitability. However, the funding is subject to certain conditions, including successful product commercialization.
Read more →LQDACERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN RED
Liquidia Technologies, Inc. has entered into an amendment for its lease agreement, extending the term by 62 months until the end of 2031. The amendment includes a structured rent schedule with increasing base rent over the extension period. Certain identified information has been redacted, which suggests potential competitive concerns. The lack of detailed public information raises questions about the company's operational status or challenges.
Read more →LQDALiquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update Received tentative approval from the FDA for YUTREPIA (treprostinil) inhalation powder for both pulmonary arterial hypertens
Liquidia Corporation reported its third quarter 2024 financial results and a corporate update, highlighting the tentative FDA approval of YUTREPIA for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company is pursuing litigation to challenge the exclusivity granted to a competing product, which may delay YUTREPIA's market launch until after May 2025. Financially, Liquidia raised approximately $100 million to strengthen its position, though it reported an increased net loss compared to the same quarter last year. Ongoing litigation expenses and increased investments in R&D are noted as challenges.
Read more →LQDA▲ +11.2%on this news
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics' Patent - U.S. Supreme Court denied United Therapeutics' petition to appeal rulings that found all claims of U.S. Patent No. 10,7
Liquidia Corporation announced that the U.S. Supreme Court denied United Therapeutics' request to review rulings that invalidated its patent. This decision finalizes the invalidation of U.S. Patent No. 10,716,793, affirming that all claims are unpatentable. Furthermore, Liquidia's YUTREPIA inhalation powder has received tentative approval from the FDA for treating pulmonary arterial hypertension. With the patent issues resolved, Liquidia is positioned to launch YUTREPIA once final approvals are obtained.
Read more →LQDALiquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606) Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere Liquidia also obtains r
Liquidia Corporation and Pharmosa Biopharm have expanded their collaboration regarding the development of L606, an inhaled, sustained-release formulation of treprostinil for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Under the amended agreement, Liquidia's licensing territory now includes key markets in Europe and Japan, while Pharmosa retains rights in several other regions. Liquidia will lead development and commercialization efforts in the expanded territory, and its recent safety data for L606 has been positive. This partnership signifies a move towards providing new treatment strategies for patients in areas lacking approved therapies.
Read more →LQDA▲ +14.1%on this news
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement MORRISVILLE, N.C.
Liquidia Corporation has announced a successful $67.5 million fundraise from a public offering and concurrent private placement, alongside an additional $32.5 million from HealthCare Royalty as part of its financing agreement. The proceeds aim to support the ongoing development of its pulmonary arterial hypertension treatment, YUTREPIA. The public offering involves the sale of over 6.4 million shares at $8.90 each, while the private placement involves nearly 1.1 million shares. Liquidia's CFO expressed optimism about the company's financial positioning and the potential approval of YUTREPIA, highlighting significant advancements in their pipeline.
Read more →LQDA▼ -30.6%on this news
U.S. FDA Grants Tentative Approval of YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) FDA co
Liquidia Corporation announced that the U.S. FDA has granted tentative approval for its inhalation powder YUTREPIA, which is intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This approval signifies that YUTREPIA has met all necessary regulatory standards, although it cannot receive final approval until a competing product's exclusivity period expires. Liquidia expressed disappointment over the FDA granting regulatory exclusivity to United Therapeutics for Tyvaso DPI, which may delay YUTREPIA's availability. The company remains focused on addressing the needs of patients suffering from these conditions.
Read more →LQDALiquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD MORRISVILLE, N.C., August 22,2024 - Liquidia Corporati
Liquidia Corporation has initiated litigation in the U.S. District Court to contest the FDA's decision granting regulatory exclusivity to Tyvaso DPI, which delays the final approval of Liquidia's YUTREPIA (treprostinil) inhalation powder. The FDA tentatively approved YUTREPIA for treating PAH and PH-ILD, but the exclusivity status awarded to Tyvaso DPI has postponed its market entry until May 2025. Liquidia aims to bring YUTREPIA to patients as soon as possible, emphasizing the need for competitive treatment options in the rare disease space.
Read more →LQDALiquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update MORRISVILLE, N.C.
Liquidia Corporation reported its financial results for the second quarter of 2024, highlighting the absence of legal obstacles for FDA approval of YUTREPIA. The company showcased its continued progress in clinical studies for both YUTREPIA and L606, presenting at prominent medical conferences. However, Liquidia recorded a net loss of $27.9 million during this quarter, an increase from the prior year's loss, alongside a decline in revenue due to reduced sales. The financial status remains stable with significant cash reserves.
Read more →LQDA▲ +12.7%on this news
District Court Issues Favorable Ruling and Denies United Therapeutics' Request to Block YUTREPIA Launch On May 31, Judge Andrews denied United Therapeutics' motion for a preliminary injunction to block the launch of YUTR
On May 31, a U.S. District Court judge denied United Therapeutics' motion to block the launch of YUTREPIA, Liquidia Corporation's inhalation powder for pulmonary hypertension. The ruling supports the FDA's potential approval of YUTREPIA, which aims to treat patients with pulmonary arterial hypertension and interstitial lung disease. Liquidia is intensifying its preparations for market entry as the legal dispute with United Therapeutics continues, set for trial in June 2025. This decision follows multiple previous rulings affirming the validity of Liquidia's product against UTHR's patent claims.
Read more →LQDALiquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update MORRISVILLE, N.C.
Liquidia Corporation announced its financial results for the first quarter of 2024 and provided updates on its YUTREPIA drug. The company is actively seeking FDA approval for YUTREPIA for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Despite certain legal challenges posed by United Therapeutics, Liquidia remains optimistic about delivering YUTREPIA to patients. The company's cash reserves have increased following successful funding efforts.
Read more →LQDAUpdate on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA (treprostinil) inhalation powder On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxma
Liquidia Corporation announced that a recent court decision has cleared a path for the FDA to finalize approval of its drug YUTREPIA (treprostinil) inhalation powder. Judge Andrews lifted an injunction that had previously halted FDA actions on the New Drug Application. Liquidia is poised to launch YUTREPIA in treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. However, United Therapeutics has filed appeals and lawsuits which may pose legal challenges ahead of the potential launch.
Read more →LQDA▲ +5.4%on this news
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update - Preparing to launch YUTREPIA (treprostinil) inhalation powder upon final FDA approval - Federal Circuit rejected request by Un
Liquidia Corporation reported its financial results for 2023, highlighting preparations for the commercial launch of YUTREPIA, an inhalation powder for PAH and PH-ILD, pending final FDA approval in March 2024. The company has experienced favorable legal outcomes that may enable a smoother market entry for YUTREPIA. However, Liquidia also reported an increased net loss year-over-year, underscoring certain financial challenges. The company plans to complete enrollment in its clinical studies and will share interim data at upcoming conferences.
Read more →LQDALiquidia Corporation Provides Update on New Drug Application for YUTREPIA (treprostinil) inhalation powder MORRISVILLE, N.C.
Liquidia Corporation announced that the FDA is reviewing its New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder. The FDA confirmed the process for adding pulmonary hypertension associated with interstitial lung disease (PH-ILD) as an indication to the NDA, but is unable to issue an action letter by the previously set goal date. No additional clinical data was requested by the FDA, indicating a potential path forward for approval, although ongoing litigation regarding patent issues may pose challenges.
Read more →LQDACONFIDENTIAL INFORMATION Liquidia Corporation Announces Updates to Operations Leadership MORRISVILLE, N.C.
Liquidia Corporation has announced updates to its operations leadership in preparation for the potential launch of YUTREPIA, an inhalation powder for pulmonary arterial hypertension. Michael Kaseta has been promoted to Chief Operating Officer while retaining his role as Chief Financial Officer, emphasizing a unified leadership strategy. Michael Hunter has also been promoted to Senior Vice President of Manufacturing Operations. The FDA has set a PDUFA goal date for January 24, 2024, to consider an amendment to YUTREPIA that includes additional indications.
Read more →LQDALiquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
Liquidia Corporation has announced significant updates on its clinical pipeline targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has enrolled its first patient in the ASCENT study for YUTREPIA and received FDA confirmation that a single pivotal trial will suffice for L606's dual indication approval. YUTREPIA is on track for tentative FDA approval by January 24, 2024, and plans for a pivotal study of L606 are underway.
Read more →LQDA▲ +8%on this newsshared move
Liquidia Corporation Announces $100 Million in New Financings - Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement - Additional advance of $25.0 million fro
Liquidia Corporation has announced a $100 million financing agreement, consisting of a $75 million private placement of common stock and a $25 million amendment to its Revenue Interest Financing Agreement with HealthCare Royalty. This financing is aimed at supporting the company’s objectives for 2024, particularly regarding the launch of its inhaled drug YUTREPIA. Investor confidence is shown through the participation of Patient Square Capital and HealthCare Royalty, potentially aiding Liquidia's path toward profitability. The stock sale was completed at a discount, which could reflect market pressures.
Read more →LQDA▲ +35.7%on this news· ran to +47% by day 3
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 ( 793 Patent) - Liquidia will pursue final FDA approval for YUTREPIA (treprostinil) inhalation - Li
Liquidia Corporation announced that the U.S. Federal Circuit affirmed a decision to invalidate all claims of United Therapeutics' Patent No. 10,716,793. This ruling enables Liquidia to seek final FDA approval for its product YUTREPIA (treprostinil) inhalation. CEO Roger Jeffs expressed enthusiasm about the court's decision, highlighting that it eliminates any valid patent claims against YUTREPIA. Liquidia now aims to address unmet medical needs for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Read more →LQDALiquidia Announces Pricing of Public Offering of Common Stock
Liquidia Corporation announced the pricing of its public offering of 3,491,620 shares of common stock at a price of $7.16 per share, aiming to raise approximately $25 million. The net proceeds will be allocated towards the commercial development of YUTREPIA and further clinical trials, including those targeting WHO Group 3 and pediatric patients. Closing of the offering is expected on December 14, 2023, subject to customary conditions. The offering was managed by BofA Securities and BTIG.
Read more →LQDALiquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update Oral arguments in appeal of 793 PTAB decision set for
Liquidia Corporation has reported its financial results for the third quarter of 2023, highlighting an ongoing commitment to advancing its YUTREPIA product for pulmonary hypertension. The company is set to present pivotal legal arguments in early December regarding a patent dispute, which could significantly impact the future of YUTREPIA's market potential. While the company anticipates a potential label expansion by January 24, 2024, a current court ruling has paused final regulatory approval. Despite an increase in operational costs and net losses, Liquidia is expanding its sales force to better position itself for commercialization.
Read more →LQDAFDA Accepts Submission to Add PH-ILD to YUTREPIA Label Sets PDUFA goal date of
Liquidia Corporation announced that the FDA has accepted its submission to amend the NDA for YUTREPIA to include the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA has set a PDUFA goal date of January 24, 2024, and confirmed that no new clinical studies are necessary for this addition. However, final approval is contingent upon the resolution of ongoing litigation with United Therapeutics and the expiration of the exclusivity granted to Tyvaso in March 2024.
Read more →LQDAUnited Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office Asserts 793 patent in new litigation filed under Hatch-Waxman Act in response to Liqu
United Therapeutics Corporation has filed a patent infringement lawsuit against Liquidia Corporation concerning the U.S. patent No. 10,716,793 related to YUTREPIA, a drug aimed at treating pulmonary hypertension. This patent had previously been ruled invalid by the U.S. Patent Trial and Appeal Board, and the case is further complicated as it may delay FDA approval for YUTREPIA. Liquidia's CEO expressed disappointment in the lawsuit but affirmed the company's commitment to defending against the claims. A resolution to the appeal regarding the patent's validity is anticipated in early to mid-2024.
Read more →LQDALiquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update MORRISVILLE, N.C.
Liquidia Corporation reported its financial results for Q2 2023, highlighting advancements in its inhaled treprostinil offerings. The company has invalidated several patents against it, positioning itself better for market entry with YUTREPIA, aiming for approval for both pulmonary arterial hypertension (PAH) and PH-ILD. However, Liquidia reported a net loss of $23.5 million during the quarter and faces ongoing litigation that could impact its product launch timeline. The company has also licensed a new product, L606, to further its treatment options in this sector.
Read more →LQDAConfidential Information Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA (treprostinil) Inhalation Powder Confidential Information - No new clinical data is required to add PH
Liquidia Corporation has submitted an amendment to the FDA for its tentatively approved NDA for YUTREPIA, seeking to include the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA has indicated that this addition will not require any new clinical information. YUTREPIA, an inhalation powder formulation of treprostinil, was initially approved for pulmonary arterial hypertension (PAH). If this amendment is accepted and subsequently approved, the medication will cater to a larger patient population.
Read more →LQDA▼ -12.8%on this newsshared move
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation - Infringement case now only focused on 793 patent, previously found to be invalid by PTAB in IPR - Federal Circuit expected to hear appeal of
The U.S. Federal Circuit has upheld all prior district court rulings in a patent litigation case involving Liquidia Corporation and United Therapeutics. Following these rulings, the focus of the case is now solely on the 793 patent, which previously had its claims found invalid by the PTAB. Liquidia remains optimistic regarding the outcome of the ongoing appeal against this patent, which could impact its forthcoming regulatory approval for YUTREPIA, a treatment for pulmonary arterial hypertension. Liquidia is preparing for the market potential of YUTREPIA and the possible addition of indications for related conditions.
Read more →LQDA▲ +11%on this news
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America Liquidia exclusively licenses North American rights to L606, an inhaled formulation of
Liquidia Corporation and Pharmosa Biopharm have formed an exclusive licensing agreement for L606, an inhaled formulation of treprostinil designed for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia will spearhead the product's development and marketing in North America, while Pharmosa will handle manufacturing. The partnership includes significant financial commitments and aims to leverage innovative drug delivery technology that could improve patient outcomes. Liquidia plans to submit a New Drug Application for L606, with a clinical trial for PH-ILD anticipated to begin in the first half of 2024.
Read more →LQDALiquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update MORRISVILLE, N.C.
Liquidia Corporation reported its financial results for Q1 2023, highlighting increased physician demand for inhaled treprostinil used in treating pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The company secured a funding agreement with HealthCare Royalty, enabling it to advance its product, YUTREPIA. However, Liquidia continues to face legal challenges regarding patent issues, which could influence its regulatory progress.
Read more →LQDALiquidia and GSK Restructure License to PRINT Technology for Inhaled Applications - New agreement supersedes the collaboration agreement entered in 2012 - GSK retains non-exclusive right to use PRINT for pre-clinical res
Liquidia Corporation announced a new, non-exclusive license agreement with GSK, replacing their previous collaboration from 2012. The restructured agreement allows Liquidia to apply its PRINT technology to various inhaled formulations, while GSK retains a limited, royalty-free license for its pre-clinical research. The deal aims to improve the development of inhaled medicines, thereby maximizing the potential patient benefits of the PRINT technology. Additionally, YUTREPIA, a drug developed using PRINT, has received FDA tentative approval for use in pulmonary arterial hypertension treatment.
Read more →LQDA▲ +15.3%on this news
Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update - Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 - Fortified financial posit
Liquidia Corporation reported its financial results for 2022 and provided an update highlighting significant progress toward the potential launch of YUTREPIA, pending resolution of ongoing litigation. The company achieved notable legal victories that may facilitate regulatory approval. Liquidia emphasizes a strengthened financial position through various funding strategies and a newly appointed leadership team to aid commercialization efforts. Despite these advancements, the company acknowledges the risks associated with pending litigation outcomes related to patent claims from United Therapeutics.
Read more →LQDA▲ +9.7%on this news
Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 ( 793 Patent) - PTAB rejects UTHR's request for rehearing of its decision in the inter
Liquidia Corporation announced that the Patent Trial and Appeal Board (PTAB) reaffirmed its decision to invalidate all claims of United Therapeutics' 793 patent. This ruling is based on prior art cited by Liquidia, which effectively undermines UTHR's patent. The PTAB also denied UTHR's request for a rehearing on this decision. CEO Roger Jeffs stated that this positive outcome brings Liquidia closer to obtaining full approval for its therapeutic product, YUTREPIA, with the company anticipating a final legal resolution by mid-2024.
Read more →LQDALiquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million - Extends cash-runway through at least 2024 - Provides flexibility to accelerate launch preparations timed with s
Liquidia Corporation has announced a Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 million, which will primarily support the launch of its inhalation powder YUTREPIA pending FDA approval. The initial funding of $32.5 million will enable Liquidia to retire existing debt and enhance its capital position. This agreement includes additional funding tranches, contingent upon various conditions, aimed at furthering the company's development and commercial strategies in treating pulmonary hypertension. Liquidia executives express confidence in their strategy and growth potential, aided by this strategic financial partnership.
Read more →LQDA▼ -5.6%on this news
Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH) - Liquidia and Sandoz will collaborate with Mainbridge He
Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial MORRISVILLE, N.C., December 5, 2022 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today a collaboration with Sandoz
Read more →LQDALiquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Company to host webcast and conference call today at 8:30 a.m.
Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update N.C., November 8, 2022 - Liquidia Corporation (NASDAQ: LQDA) ("Liquidia" or the "Company") today reported financial results for the third quarter ended September 30, 2022. The Company will host
Read more →LQDAPrecedential Opinion Panel Denies United Therapeutics' Request for Review of 793 Inter Partes Review Decision MORRISVILLE, N.C.
Opinion Panel Denies United Therapeutics' Request for Review of 793 Inter Partes Review Decision MORRISVILLE, N.C., October 27, 2022 - Liquidia Corporation (NASDAQ: LQDA) announced today that on October 26, 2022, the Precedential Opinion Panel (POP) of the United States Patent
Read more →LQDA▼ -15.8%on this news
Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on
Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T. MORRISVILLE, N.C., August 31, 2022 - Liquidia Corporation (NASDAQ: LQDA) announced today that a ruling was issued by Judge Andrews, who is presiding over the litigation filed by Un
Read more →LQDA▲ +45.3%on this news
Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent MORRISVILLE, N.C.
Receives Favorable Ruling in Inter Partes Review United Therapeutics Patent MORRISVILLE, N.C., July 19, 2022 - Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding
Read more →LQDALiquidia Announces Proposed Offering of Common Stock MORRISVILLE, N.C.
Liquidia Announces Proposed Offering of Common MORRISVILLE, N.C., April 12, 2022 - Liquidia Corporation (NASDAQ: LQDA) ("Liquidia") announced today that it has commenced an underwritten public offering of its common stock. All of the shares in the proposed offering will be sol
Read more →LQDALiquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update - Received tentative FDA approval of YUTREPIA (treprostinil) inhalation powder - Expanded use of Treprostinil Injection to inclu
Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update tentative FDA approval of YUTREPIA (treprostinil) inhalation powder use of Treprostinil Injection to include subcutaneous administration to launch YUTREPIA in late-2022 pending final
Read more →LQDALiquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million MORRISVILLE, N.C.
Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million N.C., January 7, 2022 - Liquidia Corporation (NASDAQ: LQDA) announced today the closing of a debt facility on January 7, 2022, with Silicon Valley Bank (SVB) which provides Liquidia with u
Read more →LQDA▲ +5.5%on this news· ran to +30% by day 3
Liquidia Corporation Announces Chief Executive Officer Transition MORRISVILLE, N.C.
Corporation Announces Chief Executive Officer Transition N.C., January 3, 2022 - Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022 and will continue as a director on the board. He s
Read more →LQDA▲ +5.5%on this newsshared move
Stipulation of Partial Judgment In Favor of Liquidia Filed in Hatch-Waxman Litigation MORRISVILLE, N.C.
of Partial Judgment In Favor of Liquidia Filed in Hatch-Waxman Litigation MORRISVILLE, N.C., December 29, 2021 - Liquidia Corporation (NASDAQ: LQDA) announced today that United Therapeutics Corporation (UTC) has filed a stipulation of partial judgment with respect to U.S. Pate
Read more →LQDAFDA Grants Tentative Approval for Liquidia's YUTREPIA (treprostinil) inhalation powder - First dry-powder formulation of treprostinil to meet criteria required for FDA approval - Final FDA approval may occur in October 2
Grants Tentative Approval for Liquidia's (treprostinil) inhalation powder - First dry-powder formulation of treprostinil to meet criteria required for FDA approval - Final FDA approval may occur in October 2022 or earlier upon resolution of on-going litigation - Conference ca
Read more →LQDAFDA Completes On-site Pre-Approval Inspection of Liquidia's Morrisville, North Carolina Facility - No Form 483 observations were issued during 5-day inspection MORRISVILLE, N.C.
On-site Pre-Approval Inspection of Morrisville, North Carolina Facility MORRISVILLE, N.C., August 18, 2021 - Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval Inspection (PAI) of its Morr
Read more →LQDAU.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics' Tyvaso Patent MORRISVILLE, N.C.
and Trademark Appeal Board Decides to Institute of United Therapeutics' Tyvaso Patent MORRISVILLE, N.C., August 11, 2021 - Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U
Read more →LQDALiquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder MORRISVILLE, N.C.
Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder MORRISVILLE, N.C., June 2, 2021 - Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Applicatio
Read more →LQDALiquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intrav
Generic Treprostinil Injection Now Also Available for Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intravenous MORRISVILLE, N.C., May 24, 2021 - Liquidia Corporation (NASDAQ: LQDA) ("Liquidia" or the "Company") today
Read more →LQDAConfidential Information (until released) Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update - Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery -
Confidential Information (until released) Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate the market opportunity for Treprostinil Injection by adding subcutaneous delivery New Drug Application for LIQ861 (treprostinil) Inhalation Powder financia
Read more →LQDALiquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension MORRISVILLE, N.C.
Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension MORRISVILLE, N.C., May 10, 2021 - Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (ND
Read more →LQDALiquidia Corporation Announces $21.7 Million Private Placement
Corporation Announces $21.7 Million Private Placement RESEARCH TRIANGLE PARK, N.C., April 13, 2021 - Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private
Read more →LQDALiquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 www.liquidia.com Liquidia Announces Generic Treprostinil Injection Will Be Available for Subcutaneous Route of Administration - Addressable market for
Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 www.liquidia.com Generic Treprostinil Injection Will Be Available for RESEARCH TRIANGLE PARK, N.C., March 30, 2021 - Liquidia Corporation (NASDAQ: LQDA) ("Liquidia" or the "Company") today announced that Tre
Read more →LQDACorporation Reports Full-Year 2020
Corporation Reports Full-Year 2020 Results and Provides Corporate Update RESEARCH TRIANGLE PARK, N.C., March 23, 2021 - Liquidia Corporation (NASDAQ: LQDA) ("Liquidia" or the "Company") today reported financial results for the full-year ended December 31, 2020. The Company wi
Read more →LQDALiquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 www.liquidia.com Liquidia Corporation Secures $20.5 Million Debt Facility with Silicon Valley Bank
Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 Million Debt Facility with Silicon Valley Bank TRIANGLE PARK, N.C., March 2, 2021 - Liquidia Corporation (NASDAQ: LQDA) today announced the closing of a debt facility on February 26, 2021, with Silicon Val
Read more →LQDALiquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 MEDIA RELEASE www.liquidia.com Liquidia Corporation Announces Chief Executive Officer Transition
Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 Liquidia Corporation Announces Chief Executive Officer Transition RESEARCH TRIANGLE PARK, N.C., December 14, 2020 - Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as C
Read more →LQDALiquidia Technologies, Inc. 419 Davis Drive, Suite 100 Morrisville, NC 27560 MEDIA RELEASE www.liquidia.com Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer
Liquidia Technologies, Inc. 419 Davis Drive, Suite 100 Morrisville, NC 27560 Corporation Appoints Michael Kaseta Chief Financial Officer RESEARCH TRIANGLE PARK, N.C., November 30, 2020 - Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Ch
Read more →LQDALiquidia Technologies, Inc. 419 Davis Drive, Suite 100 Morrisville, NC 27560 MEDIA RELEASE www.liquidia.com Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatmen
Liquidia Technologies, Inc. 419 Davis Drive, Suite 100 Morrisville, NC 27560 MEDIA RELEASE www.liquidia.com Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension CRL does not ci
Read more →Competitive Position
How LQDA ranks across every disease it competes inCompetitive Position is a premium feature
See how LQDA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial